In company-funded studies, participants taking the Novo Nordisk drug Wegovy had average weight loss of about 34 pounds. In a comparison group getting dummy shots, the average loss was under 6 pounds.
The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.